West China Second University Hospital
Clinical trials sponsored by West China Second University Hospital, explained in plain language.
-
New targeted drug combo aims to curb relapse in kids with rare immune disorder
Disease control Recruiting nowThis study tests whether adding the targeted drug luvometinib to standard chemotherapy improves outcomes for children with multisystem Langerhans cell histiocytosis (LCH), a rare immune cell disorder. About 120 children aged 0-18 with newly diagnosed, untreated LCH will be random…
Phase: NA • Sponsor: West China Second University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill could spare kids with rare bone disease from chemo
Disease control Recruiting nowThis study tests a new daily oral drug called luvometinib in children aged 0-18 with Langerhans cell histiocytosis (LCH) that affects certain bones. LCH is a rare condition where immune cells build up and can cause bone damage. The drug targets a faulty cell signal found in nearl…
Phase: NA • Sponsor: West China Second University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC